Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts

Diabetologia

Volumn 58, Issue 1, 2015, Pages 87-97

  Alyass, Akram ^a   Almgren, Peter ^b   Akerlund, Mikael ^b   Dushoff, Jonathan ^a   Isomaa, Bo ^c,d   Nilsson, Peter ^e   Tuomi, Tiinamaija ^f,g   Lyssenko, Valeriya ^b   Groop, Leif ^b   Meyre, David ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b LUND UNIVERSITY   (Sweden)

^c FOLKHÄLSAN RESEARCH CENTER   (Finland)

^d Folkhälsan Research Center ^*  (Finland)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF HELSINKI   (Finland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Incident type 2 diabetes; Mathematical modelling; One hour post OGTT plasma glucose; Oral glucose tolerance test; Prevention

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY MASS; EUROPEAN; FAMILY HISTORY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; ANALYSIS; BLOOD; CANADA; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; INCIDENCE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; THEORETICAL MODEL;

ADULT; BLOOD GLUCOSE; CANADA; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84916640700     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3390-x     Document Type: Article

References (41)

1. ADA Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197
2. Chen L, Magliano DJ, Zimmet PZ (2011) The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol 8:228–236
3. Fox CS, Coady S, Sorlie PD et al (2007) Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115:1544–1550
4. Vinik AI, Maser RE, Mitchell BD, Freeman R (2003) Diabetic autonomic neuropathy. Diabetes Care 26:1553–1579
5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591
6. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290:1884–1890
7. Gang H, Hai Y, Dhingra R et al (2011) A novel hypoxia-inducible spliced variant of mitochondrial death gene Bnip3 promotes survival of ventricular myocytes. Circ Res 108:1084–1092
8. Dixon JB, Zimmet P, Alberti KG, Rubino F (2011) Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med 28:628–642
9. Merlotti C, Morabito A, Pontiroli AE (2014) Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies. Diabetes Obes Metab 16:719–727
10. Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350
11. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T (2011) Risk models and scores for type 2 diabetes: systematic review. BMJ 343:d7163
12. Collins GS, de Groot JA, Dutton S et al (2014) External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol 14:40
13. Kodama S, Horikawa C, Fujihara K et al (2013) Use of high-normal levels of haemoglobin A(1C) and fasting plasma glucose for diabetes screening and for prediction: a meta-analysis. Diabetes Metab Res Rev 29:680–692
14. Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L (2009) Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 32:281–286
15. Rathmann W, Kowall B, Heier M et al (2010) Prediction models for incident type 2 diabetes mellitus in the older population: KORA S4/F4 cohort study. Diabet Med 27:1116–1123
16. Abdul-Ghani MA, Lyssenko V, Tuomi T, Defronzo RA, Groop L (2010) The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab Res Rev 26:280–286
17. Tura A, Morbiducci U, Sbrignadello S, Winhofer Y, Pacini G, Kautzky-Willer A (2011) Shape of glucose, insulin, C-peptide curves during a 3-h oral glucose tolerance test: any relationship with the degree of glucose tolerance? Am J Physiol Regul Integr Comp Physiol 300:R941–R948
18. Kanauchi M, Kimura K, Kanauchi K, Saito Y (2005) Beta-cell function and insulin sensitivity contribute to the shape of plasma glucose curve during an oral glucose tolerance test in non-diabetic individuals. Int J Clin Pract 59:427–432
19. Tschritter O, Fritsche A, Shirkavand F, Machicao F, Haring H, Stumvoll M (2003) Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabetes Care 26:1026–1033
20. Froslie KF, Roislien J, Qvigstad E et al (2013) Shape information from glucose curves: functional data analysis compared with traditional summary measures. BMC Med Res Methodol 13:6
21. Lyssenko V, Jonsson A, Almgren P et al (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359:2220–2232
22. Genter PM, Ipp E (1994) Accuracy of plasma glucose measurements in the hypoglycemic range. Diabetes Care 17:595–598
23. Sonowane M, Savory J, Cross RE, Heintges MG, Chester B (1976) Kinetic measurement of glucose with a centrifugal analyzer; hexokinase and glucose oxidase procedures compared. Clin Chem 22:1100–1101
24. (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1): S62–S69
25. Rolandsson O, Hagg E, Nilsson M, Hallmans G, Mincheva-Nilsson L, Lernmark A (2001) Prediction of diabetes with body mass index, oral glucose tolerance test and islet cell autoantibodies in a regional population. J Intern Med 249:279–288
26. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M (2007) What is the best predictor of future type 2 diabetes? Diabetes Care 30:1544–1548
27. Song SH, Hardisty CA (2009) Early onset type 2 diabetes mellitus: a harbinger for complications in later years—clinical observation from a secondary care cohort. QJM 102:799–806
28. Almgren P, Lehtovirta M, Isomaa B et al (2011) Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia 54:2811–2819
29. Manco M, Panunzi S, Macfarlane DP et al (2010) One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes Care 33:2090–2097
30. Marini MA, Succurro E, Frontoni S et al (2012) Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care 35:868–872
31. Dupuis J, Langenberg C, Prokopenko I et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42:105–116
32. Saxena R, Hivert MF, Langenberg C et al (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 42:142–148
33. Stern MP, Williams K, Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575–581
34. Gerstein HC, Santaguida P, Raina P et al (2007) Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 78:305–312
35. Investigators DT, Gerstein HC, Yusuf S et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105
36. Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
37. Boyko EJ, Gerstein HC, Mohan V et al (2010) Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabet Med 27:1226–1232
38. Abdul-Ghani MA, Abdul-Ghani T, Ali N, DeFronzo RA (2008) One hour plasma glucose concentration and the metabolic syndrome identifies subjects at high risk for future type 2 diabetes. Diabetes Care 31:1650–1655
39. Matyka KA (2008) Type 2 diabetes in childhood: epidemiological and clinical aspects. Br Med Bull 86:59–75
40. Lijmer JG, Bossuyt PM (2009) Various randomized designs can be used to evaluate medical tests. J Clin Epidemiol 62:364–373
41. Robin X, Turck N, Hainard A et al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma 12:77